Hussain Alizadeh
Overview
Explore the profile of Hussain Alizadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Teutsch B, Vancsa S, Farkas N, Szakacs Z, Vorhendi N, Boros E, et al.
BMJ Open
. 2023 Mar;
13(3):e063554.
PMID: 36918236
Introduction: Acute gastrointestinal bleeding (GIB) is a life-threatening emergency with a critical economic burden. As a result of bleeding, anaemia often requires intravenous or oral iron supplementation. Elderly patients are...
12.
Krajnc D, Spielvogel C, Grahovac M, Ecsedi B, Rasul S, Poetsch N, et al.
Front Oncol
. 2022 Oct;
12:1017911.
PMID: 36303841
Background: This study proposes machine learning-driven data preparation (MLDP) for optimal data preparation (DP) prior to building prediction models for cancer cohorts. Methods: A collection of well-established DP methods were...
13.
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary
Lovas S, Obajed Al-Ali N, Varga G, Szita V, Alizadeh H, Plander M, et al.
Pathol Oncol Res
. 2022 Oct;
28:1610645.
PMID: 36262875
Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in...
14.
Szakacs Z, Lal A, Kristensen J, Farkas N, Ritter Z, Kiss S, et al.
Adv Radiat Oncol
. 2022 Sep;
7(5):100882.
PMID: 36148378
Purpose: B-cell non-Hodgkin lymphomas (NHLs) are significant contributors to cancer-related mortality. In this single-arm, retrospective cohort study, we aimed to examine the outcomes of a radioimmunotherapeutic modality, Y-labeled ibritumomab tiuxetan...
15.
Zombori-Toth N, Kiss S, Ostarijas E, Alizadeh H, Zombori T
Surg Oncol
. 2022 Aug;
44:101824.
PMID: 35952403
Background: Complete surgical removal is currently considered to be the best treatment option for pulmonary sarcomatoid carcinoma (PSC) especially in early stage operable disease; however, the reported recurrence-free survival is...
16.
Two-Year Event-Free Survival Prediction in DLBCL Patients Based on Radiomics and Clinical Parameters
Ritter Z, Papp L, Zambo K, Toth Z, Dezso D, Veres D, et al.
Front Oncol
. 2022 Jun;
12:820136.
PMID: 35756658
Purpose: For the identification of high-risk patients in diffuse large B-cell lymphoma (DLBCL), we investigated the prognostic significance of radiomics derived from baseline [F]FDG PET/CT and clinical parameters. Methods: Pre-treatment...
17.
Tari E, Vorhendi N, Kiss S, Teutsch B, Varadi A, Sisak K, et al.
Gerontology
. 2022 Mar;
69(1):1-13.
PMID: 35314584
Background: Anaemia and osteoporotic fractures are both major health problems among older adults worldwide. Objectives: Previous studies suggest that anaemia may be associated with elevated fracture risk among older adults;...
18.
Szita V, Mikala G, Kozma A, Fabian J, Hardi A, Alizadeh H, et al.
Pathol Oncol Res
. 2022 Mar;
28:1610276.
PMID: 35295611
Despite the introduction of novel agents, multiple myeloma remains incurable for most patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor, had shown promising results in patients with translocation...
19.
Ritter Z, Zambo K, Balogh P, Szollosi D, Jia X, Balazs A, et al.
Sci Rep
. 2021 Dec;
11(1):24002.
PMID: 34907289
Cerenkov luminescence imaging (CLI) is a promising approach to image-guided surgery and pathological sampling. It could offer additional advantages when combined to whole-body isotope tomographies. We aimed to obtain evidence...
20.
Kiss S, Gede N, Hegyi P, Nagy B, Deak R, Dembrovszky F, et al.
Sci Rep
. 2021 Nov;
11(1):21916.
PMID: 34754015
Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August...